Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107937 | 0.89 | TRPV3 (0.43) | TRPV3SCN9AKIF11MEN1KMT2A | |
| SCHEMBL1107961 | 0.87 | CTSS (0.47) | MEN1KMT2AKDM4E | |
| SCHEMBL1107875 | 0.86 | TRPV3 (0.41) | TRPV3SCN9AKIF11MEN1KMT2A | |
| SCHEMBL1107878 | 0.84 | RAB9A (0.52) | MEN1KMT2AKDM4ERAB9A | |
| SCHEMBL1107881 | 0.84 | TRPV3 (0.39) | TRPV3SCN9AKIF11MEN1KMT2A | |
| SCHEMBL1107909 | 0.83 | TRPV3 (0.40) | TOP1TRPV3SCN9AMEN1KMT2A | |
| SCHEMBL1107879 | 0.82 | HSD17B1 (0.41) | TOP1TRPV3SCN9AKIF11 | |
| SCHEMBL1107929 | 0.82 | TRPV3 (0.39) | TOP1TRPV3SCN9AKIF11MEN1 | |
| SCHEMBL1107931 | 0.81 | KIF11 (0.46) | TOP1TRPV3KIF11MEN1KMT2A | |
| SCHEMBL1107966 | 0.80 | CDK2 (0.39) | TOP1TRPV3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | OXA1L, SLCO4C1, SLCO2B1 | TOP1 860/4885TRPV3 1101/4885SCN9A 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.